Clinical trials
Crohn's Disease, Active clinical trials
Below are recruiting crohn's disease, active clinical trials, each written for real people, not researchers. We’re tracking 195 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06604260RecruitingPhase 2
PET scan to measure inflammation in Crohn's and colitis
This trial uses a special PET scan called FAPi-PET to look for inflammation and scarring in the gut. It may help doctors better understand your condition and guide treatment.
Amsterdam, North HollandAges 18 years+ - NCT03167437RecruitingPhase 1/Phase 2
Vorinostat for uncontrolled Crohn’s or ulcerative colitis
This early-phase study tests vorinostat to reduce gut inflammation in people with moderate-to-severe Crohn’s disease, ulcerative colitis, or certain colitis patterns linked to chronic granulomatous disease (CGD). It also looks at whether the study’s consent process is clear and understood before starting treatment.
Bethesda, MarylandAges 18–65 - NCT04970446RecruitingPhase 1/Phase 2
Fecal transplant to restore gut microbes in Crohn’s
This Phase 1/2 study tests whether a fecal microbiome transplant (FMT) can reduce active inflammation in people with Crohn’s disease. It’s designed for people who currently have signs of active bowel inflammation and can attend regular procedure visits.
Melbourne, VictoriaAges 18–70 - NCT06180382RecruitingPhase 4
Comparing vedolizumab to higher-dose adalimumab for Crohn's disease
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
Le Kremlin-Bicêtre, PARISAges 18 years+ - NCT06113913RecruitingPhase 4
Switching from IV to under-the-skin infliximab after dose increase
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
Ghent, Oost-VlaanderenAges 18 years+ - NCT04997733RecruitingPhase 3
Stool transplant to maintain Crohn’s remission after stopping anti-TNF
This Phase 3 study tests whether transplanting stool bacteria can help people with Crohn’s stay in remission after they stop an anti-TNF medicine. It may help some patients who are currently doing well but need to come off anti-TNF treatment.
ParisAges 18–74 - NCT05040464RecruitingPhase 3
Azathioprine or methotrexate added to adalimumab for Crohn’s
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
AmiensAges 18 years+ - NCT07456566Recruiting
Self-management help for inflammatory bowel disease
This trial tests a self-management program for people with active Crohn's disease or ulcerative colitis. It aims to improve quality of life by helping you better manage your condition.
Ann Arbor, MichiganAges 18 years+ - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
Birmingham, AlabamaAges 18–80 - NCT04330846Recruiting
Study of new narrowing in Crohn’s treated with two approaches
This study looks at treatments for a new (de novo) narrow area in the bowel from Crohn’s disease. It aims to see which treatment works better at relieving blockage-type symptoms for the safest, most effective option.
Badalona, BarcelonaAges 18–80 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT04973423Recruiting
Testing extra check-ins for Crohn’s using stool tests and MRI
This study checks whether adding an extra, cross-body “transmural” evaluation (looking at inflammation throughout the bowel) improves care for adults with Crohn’s who are starting or receiving biologic (biotherapy) treatment. It uses close follow-up with stool calprotectin (a marker of gut inflammation) to see if this approach helps control inflammation.
AmiensAges 18 years+ - NCT06719622Enrolling by invitationPhase 2/Phase 3
Budesonide for Crohn's in the upper gut
This trial tests a budesonide liquid that targets inflammation in the esophagus, stomach, and duodenum (upper digestive tract) in children with Crohn's disease. It aims to see if this treatment can reduce inflammation in those areas without strong side effects.
KrakowAges 6–18 - NCT06241170Recruiting
Surgical margin study for Crohn's disease recurrence
This trial tests a specific way of cutting the bowel during surgery for Crohn's disease to see if it lowers the chance of the disease coming back. It is for people with Crohn's in the ileocecal area who are having their first surgery to remove that section.
Guangzhou, GuangdongAges 14–65 - NCT07616687RecruitingPhase 4
Testing guselkumab to improve Crohn's disease control
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
AmiensAges 18 years+ - NCT07245394Recruiting
Switching to guselkumab for inflammatory bowel disease after ustekinumab
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
Calgary, AlbertaAges 18 years+ - NCT06453720Recruiting
Predicting Crohn's treatment success with gut bacteria
This study analyzes your gut bacteria to see if it can predict how well you will respond to Crohn's disease treatments. If you are having a colonoscopy for routine care, you may be eligible.
Vancouver, British ColumbiaAges 19–80 - NCT06550310Recruiting
Nutrition and IBD treatment outcomes
This study looks at how nutrition affects people with IBD who are starting a new treatment or having surgery. Researchers want to find out if diet or body changes influence how well you recover.
LondonAges 16 years+ - NCT06953791RecruitingPhase 2
Comparing two treatments for Crohn's disease flare-ups
This trial compares a steroid called prednisolone to a special diet (aCDED with PEN) for treating Crohn's disease flare-ups. It aims to see which approach helps improve quality of life.
TübingenAges 18 years+ - NCT06972901Recruiting
Preventing Crohn's recurrence after surgery using stool tests
This trial tests if checking a stool marker (fecal calprotectin) early after surgery can guide treatment with ustekinumab to prevent Crohn's disease from coming back. It's for people who had certain bowel surgery and have at least one risk factor for recurrence.
AmiensAges 18 years+ - NCT03458195Recruiting
Crohn’s surgery follow-up for ileocecal resection patients
This study follows adults with Crohn’s disease who need surgery to remove the ileocecal area. It aims to better understand post-operative outcomes and what to expect after the operation.
LiègeAges 18–100 - NCT05733845Recruiting
Study of why some bowel inflammation treatments don’t work
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
Vandœuvre-lès-Nancy, CHRU de NancyAges 18 years+ - NCT06810518Recruiting
Studying stool test for digestive disease diagnosis
This trial tests a new stool test to measure calprotectin levels, which could help doctors tell the difference between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). If you have symptoms like stomach pain, diarrhea, or weight loss and are about to have a colonoscopy, you may be able to join.
Miami, FloridaAges 22 years+ - NCT07300553RecruitingPhase 2
Gut bacteria and energy metabolism in health and IBD
This study looks at how the bacteria living in your gut affect your body's energy use. It includes both healthy volunteers and people with inactive Crohn's disease or ulcerative colitis.
ParisAges 18–50
Hear when a new Crohn's Disease, Active trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for crohn's disease, active?
- Yes. Clin2 currently lists 195 recruiting crohn's disease, active studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a crohn's disease, active trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a crohn's disease, active trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.